Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
baca selengkapnya
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
790 hari yang lalu
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
824 hari yang lalu
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
971 hari yang lalu
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1552 hari yang lalu
Swiss Market Ends On Weak Note
The Switzerland stock market pared early gains and closed on a negative note on Wednesday as weak investor sentiment data and higher oil prices weighed.
RTTNews
|
29 menit yang lalu
European Markets Close Weak On Higher Oil Prices, U.S.-Iran Deal Uncertainty
European stocks fell on Wednesday, hurt by higher bond yields and rising oil prices amid lingering uncertainty about Iran and the U.S. reaching a deal to end their conflict and pave the way for the reopening of the Strait of Hormuz.
Some weak economic data from the region - UK GDP report being an exception - weighed as well on sentiment.
RTTNews
|
57 menit yang lalu
Chicago Business Barometer Surges Back Into Expansionary Territory In September
A report released by MNI Indicators on Wednesday showed a substantial rebound by its reading on Chicago-area business activity in the month of September. MNI Indicators said its Chicago business barometer spiked to 58.8 in September from 47.1 in August, with a reading above 50 indicating growth. Economists had expected the index to jump to 51.0.
RTTNews
|
4 jam 23 menit yang lalu
U.S. Consumer Prices Rise 0.3% In August, Slightly Less Than Expected
The Commerce Department released a closely watched report on Wednesday showing consumer prices in the U.S. rose by slightly less than expected in the month of August. The Commerce Department said its personal consumption expenditures (PCE) price index increased by 0.3 percent in August following a revised 0.1 percent uptick in July.
RTTNews
|
4 jam 39 menit yang lalu
